Does Posterior Wall Isolation Improve PFA in Persistent AF?
Catheter ablation remains a cornerstone therapy for persistent atrial fibrillation. Recently, pulsed field ablation has emerged as a promising nonthermal modality with superior myocardial tissue selectivity. However, clinicians continue to debate whether adding posterior wall isolation improves long-term rhythm control compared to pulmonary vein isolation alone.
Study Overview: The PIFPAF-PFA Randomized Trial
The PIFPAF-PFA trial investigated this critical clinical question across six centers in Switzerland. Specifically, researchers enrolled 206 patients with symptomatic persistent atrial fibrillation between November 2023 and February 2025. Investigators then randomized participants 1:1 to receive pulmonary vein isolation alone or pulmonary vein isolation plus posterior wall isolation.
Additionally, all patients received an implantable cardiac monitor following ablation. This device ensured continuous and blinded rhythm monitoring for one full year. The primary end point focused on the first recurrence of atrial tachyarrhythmia between days 91 and 365.
Primary Efficacy and Secondary Outcomes of Pulsed Field Ablation
Ultimately, the addition of posterior wall isolation did not significantly reduce primary arrhythmia recurrence. Atrial tachyarrhythmia recurred in 50.6% of patients receiving combined ablation versus 60.6% receiving pulmonary vein isolation alone. Therefore, this difference did not reach statistical significance.
However, several secondary outcomes revealed intriguing signals. First, the mean atrial arrhythmia burden decreased significantly from 11.0% with isolation alone to 6.9% with added posterior wall isolation. Furthermore, the combined strategy reduced longer arrhythmia episodes lasting one day or more. Consequently, these findings suggest potential clinical benefits regarding overall rhythm burden rather than simple binary recurrence.
Safety Profile and Clinical Implications
Importantly, the safety composite end point occurred in only two patients within the posterior wall isolation group. Neither group reported any atrioesophageal fistulas or deaths. Thus, pulsed field ablation maintained an excellent safety profile even with expanded lesion sets.
In conclusion, routine posterior wall isolation cannot yet be recommended as standard practice for all persistent cases. Nevertheless, these hypothesis-generating findings warrant larger confirmatory trials to determine which patient subsets benefit most.
Frequently Asked Questions
Q1: What was the main finding of the PIFPAF-PFA trial?
The trial found that adding posterior wall isolation to pulsed field ablation did not significantly reduce the primary rate of arrhythmia recurrence compared to pulmonary vein isolation alone.
Q2: Did adding posterior wall isolation reduce the overall arrhythmia burden?
Yes, patients receiving posterior wall isolation experienced a significantly lower mean arrhythmia burden (6.9% vs 11.0%) and fewer prolonged arrhythmia episodes.
Q3: Was pulsed field ablation safe when targeting the posterior wall?
Yes, pulsed field ablation demonstrated high safety with low complication rates and zero reported cases of atrioesophageal fistula.
References
- Roten L et al. Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation: The PIFPAF-PFA Randomized Clinical Trial. JAMA. 2026 Aug 29. doi: 10.1001/jama.2026.17598. PMID: 42667231.
- Reddy VY et al. Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2. Circulation. 2025;151:e1-e12.
- Badertscher P et al. Impact of left atrial posterior wall isolation using pulsed-field ablation in patients undergoing repeat catheter ablation for atrial fibrillation. Heart Rhythm. 2026;23(1):45-52.
